The Transplant Company™
Focused on improving care across the entire transplant patient journey
Corporate Presentation
February 28, 2024
Patrick G.
Kidney Transplant
Recipient
Safe Harbor Statement
These slides and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the future financial position of CareDx®, Inc. (together with its subsidiaries, "CareDx" or the "Company"), including financial targets, business strategy, and plans and objectives for future operations, are forward-looking statements. CareDx has based these forward-looking statements on its estimates and assumptions and its current expectations and projections about future events. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those contained in the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed or may subsequently file with the U.S. Securities and Exchange Commission (the "SEC"). In light of these risks, uncertainties and assumptions, the forward- looking events and circumstances discussed in this presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. CareDx undertakes no obligation to update publicly or revise any forward-looking statements for any reason after the date of this presentation or to conform these statements to actual results or to changes in CareDx's expectations.
These slides and the accompanying oral presentation contain certain non-GAAP financial measures, which are provided to assist in an understanding of the business and performance of CareDx. These measures should always be considered only as a supplement to, and not as superior to, financial measures prepared in accordance with GAAP. Please refer to the Appendix included in these slides for a reconciliation of the non-GAAP financial measures included in these slides and the accompanying oral presentation to the most directly comparable financial measures prepared in accordance with GAAP.
Certain data in this presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to update such data after the date of this presentation. Such data involves risks and uncertainties and is subject to change based on various factors.
The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company.
2
Office of the Chief Executive Officer Update
Michael Goldberg, Board Chairperson
Office of the Chief Executive Officer Update
Michael Goldberg | Abhishek Jain | Alex Johnson |
Board Chairperson | Chief Financial Officer | President of Patient |
& Testing Services |
- Confidence in leadership and bench strength
- Strong business performance in Q3 and Q4 2023
- Search underway for new Chief Executive Officer
4
CEO Search
- Russell Reynolds sourcing candidates
- Ideal candidate profile
- Molecular diagnostics
- Operating record
- Public company CEO
- M&A/BD
- Leadership style
- Timing
- Approximately 6 to 9 months
5
CareDx Leadership
Office of the Chief Executive Officer
Michael D. Goldberg | Abhishek Jain | Alexander L. Johnson |
BOARD CHAIRPERSON | CHIEF FINANCIAL OFFICER | PRESIDENT OF PATIENT & |
TESTING SERVICES |
Executive Leadership
Robert N. Woodward, PhD | Marica Grskovic, PhD | Kashif Rathore | GS Jha | Stacey Follon | Jeffrey A. Novack |
CHIEF SCIENTIFIC OFFICER | CHIEF OPERATIONS OFFICER | CHIEF OF PATIENT AND | SVP, CHIEF INFORMATION | SENIOR VICE PRESIDENT, | GENERAL COUNSEL |
DIGITAL SOLUTIONS | OFFICER & CHIEF | HEAD OF HUMAN | |||
INFORMATION SECURITY | RESOURCES | ||||
OFFICER |
6
Transplant Vision and Growth Strategy
Alex Johnson, President of Patient & Testing Services,
Office of the Chief Executive Officer
Patrick G. Kidney Transplant Recipient
Our Vision
The leading partner for the transplant ecosystem
Our Mission
We are committed to improving long-term outcomes by providing innovative solutions throughout the entire transplant patient journey
8
CareDx Key Highlights
1
2
3
4
5
We are in early stages of a $6B+ market opportunity in transplant care, serving some of the highest need patients in the US healthcare system
Our strategy is to develop and provide best in class, reimbursed high value clinical solutions to patients to extend allograft survival
Our ability to 'go deep' in transplant enables us to understand the unmet clinical needs in the market and continue our leadership
We will continue to innovate and redefine patient care with the team that brought sequencing and AI innovation to the transplant clinic
We are set up to efficiently allocate capital to deliver growth and strong shareholder returns
9
Serving High-Cost Patient Population with Large Unmet Need
Delivering Clinical Solutions to Help Extend Allograft Survival
Transplant Patients Need
Better Care
- Among highest need patients in US healthcare system
- Within 5 years of transplant:1
- 1 in 5 kidneys fail
- 1 in 3 hearts fail
- 1 in 2 lungs fail
- Next generation:
- Unmet need: Balance immunosuppression & infection rejection
- End stage renal disease is costly: ~$37B in 20202
- ~6.1% of ALL Medicare expenditures in 20202
- Transplantation is more cost-effective:
- Annual Centers for Medicaid & Medicare Services (CMS) spend on kidney transplant maintenance is less than half dialysis cost2
Opportunity to Improve Care Along
Transplant Patient Journey
- Created market standard in gene expression profiling with AlloMap and in dd-cfDNAsurveillance with AlloSure
- Improving clinical utility through combination of multi- modality surveillance technologies
- Driving better patient management and adherence with a robust suite of digital health tools
- Creating future standards for xenotransplant, and stem cell and cell transplant monitoring
1.HRSA OPTN Data; 2. NIH NIDDK, United States Renal Data System (USRDS) 2022 Annual Data Report (ADR).
10
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
CareDx Inc. published this content on 01 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 March 2024 16:45:06 UTC.